DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.

This clinical trial is looking at a drug called entrectinib. Entrectinib is approved as standard of care treatment for adult patients with non-small cell lung cancer (NSCLC) which have a particular molecular alteration called ROS1-positive, and patients 12 years old or above with solid tumours which have another type of change in the cancer cells. This means it has gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Investigators now wish to find out if it will be useful in treating patients with other cancer types which

Trial Details

NCT ID

NCT05770544

Phase

PHASE2 / PHASE3

Sponsor

Cancer Research UK

Status

RECRUITING

Cancer Type

Brain Cancer

Interventions

Entrectinib

Locations (sample)

Belfast, United Kingdom|54.59682,-5.92541
Birmingham, United Kingdom|52.48142,-1.89983
Birmingham, United Kingdom|52.48142,-1.89983
Bristol, United Kingdom|51.45523,-2.59665
Bristol, United Kingdom|51.45523,-2.59665

Key Eligibility Criteria

Inclusion Criteria:
A. Confirmed diagnosis of a ROS1 gene fusion-positive malignancy, other than NSCLC, that has been identified using an analytically validated next-g…
B. Patients must be able and willing to undergo a fresh tissue biopsy at baseline and blood samples for translational research. Note that for patie…
C. Patients with a BSA of 0.43m\^2 and over.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Brain Cancer Trials on Trialify →